LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Search

Insulet Corp

Closed

SectorHealthcare

144.75 1.41

Overview

Share price change

24h

Current

Min

141.49

Max

144.77

Key metrics

By Trading Economics

Income

-11M

91M

Sales

-22M

762M

P/E

Sector Avg

36.269

50.102

EPS

1.3

Profit margin

11.96

Employees

5,400

EBITDA

-23M

154M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+60.9% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-1.1B

11B

Previous open

143.34

Previous close

144.75

News Sentiment

By Acuity

46%

54%

143 / 344 Ranking in Healthcare

Insulet Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 maj 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

Peer Comparison

Price change

Insulet Corp Forecast

Price Target

By TipRanks

60.9% upside

12 Months Forecast

Average 229.53 USD  60.9%

High 294 USD

Low 154 USD

Based on 21 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

17

Buy

3

Hold

1

Sell

Sentiment

By Acuity

143 / 344 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat